Anzeige
❌
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A2JDHD | ISIN: IL0011417206 | Ticker-Symbol: 4SG
Frankfurt
25.04.25
08:03 Uhr
0,585 Euro
+0,040
+7,34 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SOL-GEL TECHNOLOGIES LTD Chart 1 Jahr
5-Tage-Chart
SOL-GEL TECHNOLOGIES LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,5800,77509:18

Aktuelle News zur SOL-GEL TECHNOLOGIES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
SOL-GEL TECHNOLOGIES Aktie jetzt für 0€ handeln
17.04.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer2SEC Filings
17.04.Sol-Gel secures $16 million, extends cash runway1Investing.com
17.04.Sol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.228GlobeNewswire (Europe)Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610...
► Artikel lesen
01.04.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer3SEC Filings
18.02.Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer-SEC Filings
20.11.24Sol-Gel announces 180-day extension period for Nasdaq compliance5Seeking Alpha
20.11.24Sol-Gel receives Nasdaq compliance extension2Investing.com
15.11.24Sol-Gel Technologies GAAP EPS of -$0.01 beats by $0.04, revenue of $5.36M beats by $1.16M2Seeking Alpha
15.11.24Sol-Gel Technologies Ltd.: Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates174GlobeNewswire (Europe)Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210...
► Artikel lesen
15.11.24Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer-SEC Filings
04.11.24Sol-Gel Technologies Ltd. - 6-K, Report of foreign issuer1SEC Filings
16.08.24Sol-Gel Technologies Ltd.: Sol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate Updates221GlobeNewswire (Europe)Following recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with...
► Artikel lesen
20.05.24Sol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates222GlobeNewswire (Europe)Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China...
► Artikel lesen
16.05.24Sol-Gel Technologies Ltd.: Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO in the Mainland of China, Hong Kong, Macau, Taiwan and Israel200GlobeNewswire (Europe)NESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a...
► Artikel lesen
14 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1